ClinicalTrials.gg
CompletedNCT02722239Updated Feb 19, 2018Results posted

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

A Phase 1 interventional study of Xigduo XR and Metformin ER (Glucophage® long) in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
203rd of 287
40 · median 100
Started
2016
with 12 others
Phase 1
55 of 293
2 open now
Registered
212th of 293
by date
Lead sponsor
19 of 293
AstraZeneca

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 203rd largest by enrollment of the 287 interventional ones that give a count, is one of 13 that started in 2016, is one of 55 in phase 1, and was the 212th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate bioequivalence of fixed dose combination Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg, (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), ER tablets, 1000 mg (2 x 500 mg) (Merck Santé S.A.S., France) which are already registered in the Russian Federation.

Read the detailed description

Randomised open-label crossover comparative, single center, two periods, clinical study of investigational drug and reference drugs bioequivalence evaluation with a single administration of the study drug (1 modified - release film-coated tablets of Dapagliflozin + Metformin or 1 film-coated tablets of Forxiga™ + 2 tablets ER of Glucophage® long) under fed condition in healthy volunteers.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Xigduo;
  • bioequivalence;
  • crossover;
  • Russia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The volunteer is able to understand the requirements of the study, to sign the form, and agrees with all the restrictions imposed in the course of the study;
  2. Male and female subjects aged 18-45, inclusive;
  3. Caucasian race;
  4. Body-mass index () within the range dated 18.5 to 30 kg/m2;
  5. Verified diagnosis "healthy" as confirmed by the results of standard clinical, laboratory, and instrumental evaluations;
  6. A negative pregnancy test at the Screening Visit for female subjects of .

    (no menses for at least 1 year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) females are exempted from the requirement. In case of using hormonal , these should be withdrawn at least 2 months before the study;

  7. Volunteers' with preserved agree to use adequate contraception throughout the study and for 30 days thereafter

Exclusion criteria

Exclusion Criteria:

  1. Known or intolerance to dapagliflozin or metformin or any other of the study drugs;
  2. History of allergy to Na+ glucose co-transport inhibitor;
  3. Complicated allergic history including food intolerance;
  4. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
  5. Chronic diseases of the cardiovascular, bronchopulmonary, nervous, endocrine, or musculoskeletal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood, immune system, mental disorders;
  6. Deviations from the normal parameters in clinical blood count analysis, biochemical blood analysis, urinalysis; vital signs;
  7. Mental, physical and other reasons that do not allow the subjects according to investigator's opinion to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort;
  8. Organic brain damage, history of increased seizure activity;
  9. Changes on ();
  10. Systolic blood pressure (AD) measured in a sitting position, less than 100 mmHg or above 130 mmHg and / or diastolic blood pressure below 70 mm Hg or above 90 mmHg at screening or any time during the study;
  11. Heart rate less than 60 or more than 80 beats per minute at screening or prior to administration of the drug in each period of the study;
  12. Scheduled radioisotope or radiological examinations using iodinated contrast agents during \< 2 days before dosing;
  13. Rare hereditary diseases manifestating with fructose or sorbitol intolerance;
  14. Gastrointestinal tract surgery (except appendectomy);
  15. Acute infectious diseases less than 4 weeks before the start of the study;
  16. Regular medication (including dietary supplements and combination herbal medicinal products) and vitamins intake within 2 weeks (or 6 half-lives, whichever is longer) prior inclusion into the study and subject does not give agreement to refuse from this medication until the end of study;
  17. Administration of the medicines that have a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazol, zimetidin etc.) less than 30 days before the start of the study;
  18. Blood donation (450 ml and more of blood or plasma) less than 2 months before the start of the study;
  19. Participation in another clinical study within 3 months before the start of the study;
  20. Alcohol intake > 10 units of alcohol per week (1 unit of alcohol - 500 ml of beer, 200 ml of dry wine or 50 ml of strong alcoholic beverages) or history of alcohol abuse, narcomania or other drug abuse.
  21. Use of alcohol and/or caffeinated and xanthine containing substances (for example, coffee, tea, colas, energetic drinks), chocolate as well as citrus fruits and cranberry (including juices, fruit drinks, etc.) 72 hours prior and throughout the study.
  22. Smoker (>10 cigarettes per day) and/or inability to refrain from smoking on Period I and Period II
  23. Special diets (e.g. vegetarians or hypocaloric diet [ less than 1000 cal/day]) or lifestyle (including night work and extreme physical activities, such as sports or weight lifting), which may impede the study conduction and monitoring;
  24. Positive screening blood test for surface antigen (HBsAg), (HCV) antibody, (HIV-1or HIV-2 antibodies) and / or syphilis (RW);
  25. A positive drug urine screening (cocaine, opiates, cannabis, barbiturates, amphetamines);
  26. A positive alcohol breath test;
  27. Dehydration due to diarrhea, vomiting or another cause during the last 24 hours before the start of the study;
  28. There is any concern by the investigator regarding the safe participation of the subject in the study or for any other reason; the investigator considers the subject ineligible for the study.
  29. Breast-feeding period;
  30. For women - Use of hormonal for 2 months before the study start;
  31. Female volunteers with , having unprotected sexual intercourse with any unsterilized male partner (i.e., a man that is not sterilized by vasectomy for at least 6 months) for 30 days before receiving study medication.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    T/R

    Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)

    Drug: Xigduo XR · Drug: Metformin ER (Glucophage® long) · Drug: Dapagliflozin (Forxiga)

  • Experimental
    R/T

    Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.

    Drug: Xigduo XR · Drug: Metformin ER (Glucophage® long) · Drug: Dapagliflozin (Forxiga)

Interventions

  • DrugXigduo XR

    a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release

  • co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).

  • co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax).

    Time frame: Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.

  2. Area Under the "Concentration - Time" Curve (AUC0-t)

    Time frame: Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.

  3. Area Under the "Concentration - Time" Curve (AUC0-∞)

    Time frame: Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.

  4. Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios

    The drugs are considered bioequivalent if the 90% confidence intervals for the Test : Reference products geometric least squares mean ratios of AUC, Cmax и Cmax/AUC parameters are in the range of 80% - 125%.

    Time frame: Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.

  5. Adverse Events

    Adverse events data for Dapagliflozin + Metformin, modified-release film-coated tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) and for co-administered Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg, (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), XR tablets, 500 mg/2 tablets (Merck Santé S.A.S, France)

    Time frame: AE information will be collected from the time of the first dosing to the last study procedure made in the hospital, approximately 1 month

07

Results

Posted Feb 19, 2018

Participant flow

Participants recruited from one medical clinic located in Moscow, Russia in March and April 2016.

Participant flow — Overall Study
MilestoneT Drug First / Then Drug RR Drug First / Then Drug T
Started2020
First intervention (1 day)2020
Washout (7 days)2020
Second intervention (1 day)2020
Completed2020
Not completed00

Outcome measures

PrimaryMaximum Concentration (Cmax).
Time frame:
Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.
Reported as:
Mean · ug/ml
Maximum Concentration (Cmax).
ug/mlTest Product (T)Reference Product (R)
Dapagliflozin Cmax [ug/ml]: Mean (± SD)90.883 ± 25.30295.975 ± 25.135
Metformin Cmax [ug/ml]: Mean (± SD)1030.83 ± 258.910986.93 ± 255.277
PrimaryArea Under the "Concentration - Time" Curve (AUC0-t)
Time frame:
Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.
Reported as:
Mean · ug/mL*h
Area Under the "Concentration - Time" Curve (AUC0-t)
ug/mL*hTest Product (T)Reference Product (R)
Dapagliflozin AUC0-t [ug/mL*h]: Mean (± SD)505.964 ± 130.420511.293 ± 127.715
Metformin AUC0-t [ug/mL*h]: Mean (± SD)8858.52 ± 2998.499286.92 ± 3222.38
PrimaryArea Under the "Concentration - Time" Curve (AUC0-∞)
Time frame:
Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.
Reported as:
Mean · ug/mL*h
Area Under the "Concentration - Time" Curve (AUC0-∞)
ug/mL*hTest Product (T)Reference Product (R)
Dapagliflozin AUC0-∞ [ug/mL*h]: Mean (± SD)521.295 ± 136.036532.556 ± 144.768
Metformin AUC0-∞ [ug/mL*h]: Mean (± SD)9408.51 ± 3373.659612.23 ± 3440.33
PrimaryBioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios

The drugs are considered bioequivalent if the 90% confidence intervals for the Test : Reference products geometric least squares mean ratios of AUC, Cmax и Cmax/AUC parameters are in the range of 80% - 125%.

Time frame:
Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.
Reported as:
Least squares mean · Geometric least squares mean ratio (%)
Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios
Geometric least squares mean ratio (%)T Drug vs R Drug
Dapagliflozin AUC0-t %99.0829 (95.943 to 102.326)
Dapagliflozin Cmax %94.7712 (87.887 to 102.194)
Dapagliflozin Cmax/AUC0-t %95.6484 (89.102 to 102.675)
Metformin AUC0-t %95.9105 (89.492 to 102.79)
Metformin Cmax %104.3772 (98.492 to 110.614)
Metformin Cmax/AUC0-t %108.8277 (101.607 to 116.561)
PrimaryAdverse Events

Adverse events data for Dapagliflozin + Metformin, modified-release film-coated tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) and for co-administered Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg, (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), XR tablets, 500 mg/2 tablets (Merck Santé S.A.S, France)

Time frame:
AE information will be collected from the time of the first dosing to the last study procedure made in the hospital, approximately 1 month
Reported as:
Number · adverse event
Adverse Events
adverse eventTest Product (T)Reference Product (R)
Adverse Events3431

Adverse events

Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product (T)—0/40 (0%)20/40 (50%)
Reference Product (R)—0/40 (0%)19/40 (47.5%)
Most frequent other events
Most frequent other events
EventTest Product (T)Reference Product (R)
pH urine decreasedInvestigations15/4010/40
Glucose urine presentInvestigations13/409/40
Specific gravity urine decreasedInvestigations5/408/40
Haematocrit increased in hematologyInvestigations0/402/40

Baseline characteristics

The age range of the study healthy volunteers was 19-44 years.

Age, Continuous
Age, Continuous(years)T Drug First / Then Drug RR Drug First / Then Drug TTotal
Age (years): Mean ± Standard Deviation29.6 ± 7.730.8 ± 8.730.2 ± 8.1
Age, Customized
Age, Customized(participants)T Drug First / Then Drug RR Drug First / Then Drug TTotal
<18 years000
between 18 and 45 years (inclusive)202040
>45 years000
Sex: Female, Male
Sex: Female, Male(Participants)T Drug First / Then Drug RR Drug First / Then Drug TTotal
Female91019
Male111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T Drug First / Then Drug RR Drug First / Then Drug TTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202040
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Research Site
    Moscow, 123423, Russian Federation
09

References and documents

Publications

  • Khomitskaya Y, Tikhonova N, Gudkov K, Erofeeva S, Holmes V, Dayton B, Davies N, Boulton DW, Tang W. Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. Clin Ther. 2018 Apr;40(4):550-561.e3. doi: 10.1016/j.clinthera.2018.02.006. Epub 2018 Mar 14. PubMed 29548719 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in May 2016, 1 month.

Results were first posted in Feb 2018, 1 year 9 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 29, 2016
StartActual
Mar 30, 2016
Primary completionActual
May 5, 2016
CompletionActual
May 5, 2016
Results first posted
Feb 19, 2018
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02722239
Lead sponsor
AstraZeneca
Collaborators
Biocard
Responsible party
Sponsor
First posted
Mar 29, 2016
Start date
Mar 30, 2016
Primary completion
May 5, 2016
Completion
May 5, 2016
Results posted
Feb 19, 2018
Last update
Feb 19, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Dapagliflozin

Start the discussion